Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Psychiatry
Volume 2013 (2013), Article ID 926395, 3 pages
http://dx.doi.org/10.1155/2013/926395
Case Report

Manic-Like Psychosis Associated with Elevated Trough Tacrolimus Blood Concentrations 17 Years after Kidney Transplant

1Department of Medical-Surgical Sciences and Biotechnologies, UOD Fiorini Hospital, Sapienza University of Rome, Viale dell'Universitá No. 30, 00185 Rome, Italy
2Department of Neurology and Psychiatry, Sapienza University of Rome, Viale dell'Universitá No. 30, 00185 Rome, Italy

Received 2 April 2013; Accepted 26 April 2013

Academic Editors: S. Cortese, T. Hyphantis, and T. Suzuki

Copyright © 2013 Giuseppe Bersani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Q. Wu, C. Marescaux, V. Wolff et al., “Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation,” European Neurology, vol. 64, no. 3, pp. 169–177, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Ozawa, “Effects of FK506 on Ca2+ release channels (review),” Perspectives in Medicinal Chemistry, vol. 2008, no. 2, pp. 51–55, 2008. View at Google Scholar
  3. V. N. Sehgal, G. Srivastava, and S. Dogra, “Tacrolimus in dermatology—pharmacokinetics, mechanism of action, drug interactions, dosages, and side effects: part I,” SKINmed, vol. 7, no. 1, pp. 27–30, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Wallemacq, V. W. Armstrong, M. Brunet et al., “Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the european consensus conference,” Therapeutic Drug Monitoring, vol. 31, no. 2, pp. 139–152, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. C. E. Staatz and S. E. Tett, “Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation,” Clinical Pharmacokinetics, vol. 43, no. 10, pp. 623–653, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. W. P. D. Lemahieu, B. D. Maes, K. Verbeke, and Y. Vanrenterghem, “CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus,” American Journal of Transplantation, vol. 4, no. 9, pp. 1514–1522, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Agarwala, E. Culligan, A. Jain et al., “Evaluation of renal function in transplant patients on tacrolimus therapy,” Journal of Clinical Pharmacology, vol. 42, no. 7, pp. 798–805, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. W. J. Jusko, A. W. Thomson, J. Fung et al., “Consensus document: therapeutic monitoring of tacrolimus (FK-506),” Therapeutic Drug Monitoring, vol. 17, no. 6, pp. 606–614, 1995. View at Google Scholar · View at Scopus
  9. S. H. Y. Wong, “Therapeutic drug monitoring for immunosuppressants,” Clinica Chimica Acta, vol. 313, no. 1-2, pp. 241–253, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Chegounchi, M. G. Hanna, and G. H. Neild, “Progressive neurological disease induced by tacrolimus in a renal transplant recipient: case presentation,” BMC Nephrology, vol. 7, article 7, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Girard, M. Simard, R. Noiseux et al., “Late-onset-psychosis: cognition,” International Psychogeriatrics, vol. 23, no. 8, pp. 1301–1316, 2011. View at Publisher · View at Google Scholar
  12. P. Naik, M. Madhavarapu, P. Mayur, K. S. Nayak, and V. Sritharan, “Pharmacokinetics of tacrolimus in adult renal transplant recipients,” Drug Metabolism and Drug Interactions, vol. 27, no. 3, pp. 151–155, 2012. View at Publisher · View at Google Scholar
  13. W. Lemahieu, B. Maes, K. Verbeke, P. Rutgeerts, K. Geboes, and Y. Vanrenterghem, “Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea,” American Journal of Transplantation, vol. 5, no. 6, pp. 1383–1391, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Margarit, A. Rimola, I. Gonzalez-Pinto et al., “Efficacy and safety of oral low-dose tacrolimus treatment in liver transplantation,” Transplant International, vol. 11, supplement 1, pp. S260–S266, 1998. View at Google Scholar · View at Scopus
  15. E. Corruble, C. Buhl, D. Esposito et al., “Psychosis associated with elevated trough tacrolimus blood concentrations after combined kidney-pancreas transplant,” International Journal of Neuropsychopharmacology, vol. 9, no. 4, pp. 493–494, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Krishna, J. Chiappelli, B. A. Fischer, and S. Knight, “Tacrolimus-induced paranoid delusions and fugue-like state,” General Hospital Psychiatry, vol. 35, no. 3, pp. 327.e5–327.e6, 2013. View at Publisher · View at Google Scholar
  17. W. O. Bechstein, “Neurotoxicity of calcineurin inhibitors: impact and clinical management,” Transplant International, vol. 13, no. 5, pp. 313–326, 2000. View at Google Scholar · View at Scopus